Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications
Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Baseline Characteristics, Drug Exposure, and Outcomes in an Exploratory Analysis From ODYSSEY-HCM.
Journal: Journal of the American College of Cardiology
Published: October 18, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.
Journal: Circulation. Heart failure
Published: May 09, 2025
Response to Mavacamten in Patients With High Baseline Left Ventricular Filling Pressures in the EXPLORER-HCM Trial.
Journal: Circulation. Cardiovascular imaging
Published: April 08, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy.
Journal: JAMA cardiology
Published: March 05, 2025
Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Journal: Circulation
Published: November 04, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.
Journal: Circulation. Heart failure
Published: August 01, 2024
Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial.
Journal: Journal of cardiac failure
Published: June 07, 2024
Exercise Testing to Unmask Latent LVOT Obstruction in a Highly Symptomatic Patient With Hypertrophic Cardiomyopathy.
Journal: Journal of the American College of Cardiology
Published: May 23, 2024
The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry.
Journal: Journal of cardiac failure
Published: April 02, 2024
Last Updated: 09/26/2026